Video

Dr. Mohile on Using a Geriatric Assessment in Older Patients With Cancer

Supriya Gupta Mohile, MD, MS, professor of medicine and surgery, James Wilmot Cancer Institute, director, Geriatric Oncology Clinic, University of Rochester, discusses pooled findings with a geriatric assessment for older patients with cancer in an interview with OncLive during the 2018 ASCO Annual Meeting.

Supriya Gupta Mohile, MD, MS, professor of medicine and surgery, James Wilmot Cancer Institute, director, Geriatric Oncology Clinic, University of Rochester, discusses clustered findings with a geriatric assessment for older patients with cancer in an interview with OncLive during the 2018 ASCO Annual Meeting.

A geriatric assessment is a standardized tool to assess health status in older adults, using age, comorbidity, and performance status. However, those characteristics are not the most effective way to identify patients at highest risk of poor outcomes, Mohile explains. Evidence suggest that geriatric assessments can help oncologists identify patients who are at the highest risk of adverse outcomes, such as toxicity from treatment, hospitalization, mortality, and functional decline. These have also been published in recent ASCO guidelines, she adds.

Patients aged 70 and older may have medical conditions other than cancer that would make them unlikely candidates for clinical trials, but their life expectancy is often long enough to warrant cancer treatment; however, there are limited data for these patients. Mohile questions how oncologists can improve conversations about issues that older patients and caregivers care about, and how the geriatric assessment can be used to do that.

The clustered study showed that providing a geriatric assessment summary to oncologists increases the number and quality of discussions about age-related concerns and improves patient satisfaction.

<<< 2018 ASCO Annual Meeting

Related Videos
Binod Dhakal, MD
Jill Corre, PharmD, PhD
Saad Z. Usmani, MD, MBA, FACP, FASCO
Ashraf Z. Badros, MBCHB
Thierry Andre, MD, professor, medical oncology, Sorbonne Université; head, Medical Oncology Department, Saint Antoine Hospital
Sanjay Popat, BSc, MBBS, FRCP, PhD, consultant medical oncologist, The Royal Marsden Hospital; professor, thoracic oncology, the Institute of Cancer Research
Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, co-leader, kidney cancer program, Dana-Farber Cancer Institute; Jerome and Nancy Kohlberg Chair, professor, medicine, Harvard Medical School
Angeles A. Secord, MD, MHSc, professor, obstetrics and gynecology, Duke Cancer Institute, discusses findings from the phase 2 PICCOLO trial (NCT05041257) investigating mirvetuximab soravtansine-gynx (Elahere) in patients with recurrent, platinum-sensitive ovarian cancer with high folate receptor alpha (FRα) expression.
Nancy U. Lin, MD, associate chief, Division of Breast Oncology, Susan F. Smith Center for Women’s Cancers, director, Metastatic Breast Cancer Program, director, Program for Patients with Breast Cancer Brain Metastases, Dana-Farber Cancer Institute; professor, medicine, Harvard Medical School
Nicolas Girard, MD, professor, respiratory medicine, Versailles Saint Quentin University; head, Curie-Montsouris Thorax Institute, chair, Medical Oncology Department, Institut Curie